InsiderTrades

Form 4/A for ORMP ORAMED PHARMACEUTICALS INC.

Accepted 2022-01-11 00:00:00 ET · period of report 2022-01-03 · accession 0001213900-22-001613 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DA 2022-01-11 2022-01-03 ORMP KIDRON NADAV Pres, CEO, Dir F - Tax $13.89 -48.8K 867.7K -5% -$677.2K
DMA 2022-01-11 2022-01-03 ORMP KIDRON NADAV Pres, CEO, Dir A - Grant — +213.0K 916.5K +30% —
DA 2022-01-11 2022-01-03 ORMP KIDRON NADAV Pres, CEO, Dir A - Grant $0.00 +107.0K 107.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-03 F D 48,752 $13.89 867,729 D — — (F2) Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022.
2 Common Common Stock 2022-01-03 A A 63,000 — 930,729 D — — (F3) Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. (F4) This amendment is being filed to correct an administrative error in the Form 4 filed by Mr. Kidron, which reported that 950,729 shares of common stock are beneficially owned by him following the reported transactions. Mr. Kidron beneficially owned 930,729 shares of common stock following the reported transactions.
3 Common Common Stock 2022-01-03 A A 150,000 — 916,481 D — — (F1) Represents Common Stock granted by the Issuer that vested upon grant.
4 Derivative Stock Option (right to buy 2022-01-03 A A 107,000 $0.00 107,000 D $13.89 · — to 2032-01-03 107,000 Common Stock (F5) The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.